6939.TWO TFBS Bioscience Inc.
- Market cap
- TWD 642M
- P/E
- -
- P/B
- 0.57x
- ROE
- -6.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6939.TWO undervalued?
Graham numberThe Graham number of TFBS Bioscience Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TFBS Bioscience Inc. fundamental analysis
No fundamental analysis for TFBS Bioscience Inc. yet.
TFBS Bioscience Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TFBS Bioscience Inc.
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.
Full company profileTFBS Bioscience Inc. financial statements
TFBS Bioscience Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 119M | 161M | 253M | 232M | 181M | 193M |
| Gross Profit | 34.6M | 54.0M | 104M | 63.3M | 37.5M | 36.8M |
| Operating Income | 311K | 6.01M | 33.8M | -5.45M | -61.2M | -78.0M |
| EBITDA | 25.9M | 32.8M | 68.3M | 64.2M | 2.24M | -19.3M |
| Net Income | 296K | 6.12M | 27.7M | 4.91M | -38.7M | -74.5M |
| EPS | 0.01 | 0.18 | 0.80 | 0.14 | -1.11 | -2.13 |
| Balance Sheet | ||||||
| Total Assets | 288M | 491M | 1.36B | 1.45B | 1.50B | 1.46B |
| Total Liabilities | 40.4M | 66.4M | 126M | 187M | 265M | 295M |
| Shareholders' Equity | 248M | 425M | 1.24B | 1.26B | 1.23B | 1.16B |
| Cash & Short-term Investments | 76.1M | 241M | 1.03B | 979M | 694M | 307M |
| Total Debt | 19.7M | 21.4M | 52.2M | 132M | 196M | - |
| Cash Flow | ||||||
| Operating Cash Flow | 29.4M | 21.0M | 78.7M | 36.5M | 28.8M | -9.74M |
| Capital Expenditure | 13.3M | 19.0M | 49.8M | 55.9M | 373M | 225M |
| Free Cash Flow | 16.1M | 1.98M | 28.9M | -19.4M | -344M | -235M |
| Ratios | ||||||
| ROE | 0.1% | 1.4% | 2.2% | 0.4% | -3.1% | -6.4% |
| ROA | 0.1% | 1.2% | 2.0% | 0.3% | -2.6% | -5.1% |
| Net Profit Margin | 0.2% | 3.8% | 11.0% | 2.1% | -21.4% | -38.6% |
| Debt to Equity | 0.08x | 0.05x | 0.04x | 0.10x | 0.16x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TFBS Bioscience Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 9, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 1.74M | 0.05 | - |
| 2023 | TWD 3.35M | 0.10 | 68.2% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1040:1000 on Sep 27, 2023.
Who owns TFBS Bioscience Inc.
Ownership data of TFBS Bioscience Inc. is not available yet.
TFBS Bioscience Inc. company profile
- Company name
- TFBS Bioscience Inc.
- Ticker
- 6939.TWO
- ISIN
- TW0006939002
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- December
- Address
- No.103, Ln. 169, New Taipei City, Taiwan
- Phone
- 886 2 2694 7888
- Website
- tfbsbio.com
About TFBS Bioscience Inc.
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.
TFBS Bioscience Inc. management
3- Dr. Tatung Yuan Ph.D.Chairman & CEO
- Mr. Wilson LiaoChief Financial Officer
- Ms. Man Shiow JiangChief Technology Officer